Mighty Therapeutics
PrivateLast Round
Take Private
Nov 16, 2022
Est. Valuation
$27.58M
Total Funding Raised
$160M
Company Overview
Mighty Therapeutics operates in Healthcare & Life Sciences and is based in Needham, Massachusetts. Its latest recorded funding round was a Private Placement round in April 2022.
Mighty Therapeutics is a biotechnology company that develops and commercializes novel therapies for rare and age-related diseases involving mitochondrial dysfunction.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Patient Engagement
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Mighty Therapeutics Comparables
Compare Mighty Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Astellas Pharma Inc. | 78% | |
| Khondrion | 77% | |
| Pretzel Therapeutics | 73% |
For institutional investors. Book with your work email.
Mighty Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Take Private | Nov 16, 2022 | ||||
| Take Private | Aug 1, 2022 | ||||
| Private Placement | Apr 13, 2022 | ||||
| Private Placement | Apr 11, 2022 | ||||
| Debt | Oct 4, 2021 | ||||
Private Placement | Feb 10, 2021 |
For institutional investors. Book with your work email.
Mighty Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Jefferies | IPO |
| H.C. Wainwright & Co. | IPO |
| Morningside Ventures | Convertible Debt, Corporate Funding |
| Evercore | IPO |
| Atlantis Investment Management | Convertible Debt |
| CMBC Capital Holdings Limited | Convertible Debt |
| Sagamore Investments | Convertible Debt |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 16, 2022
Raised $10M with J. Wood Capital Advisors
- Apr 11, 2022
Raised $9M in a private placement round.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- partners_withSep 16, 2026
On Sep 15th '26, Mighty initiates a research collaboration with PolG Foundation and research partners to develop a novel preclinical mouse model for Parkinson’s disease, POLG-related mitochondrial disorders, and other neurodegenerative mitochondrial diseases in Massachusetts.
- partners_withSep 16, 2026
On Sep 15th '26 in Massachusetts, Mighty and JAX initiate a research collaboration to develop a novel preclinical mouse model for Parkinson’s disease, POLG-related mitochondrial diseases, and other neurodegenerative mitochondrial diseases.
- is_developingSep 16, 2026
Mighty initiates a research collaboration with The POLG Foundation, Neuroscience Research Australia, and The Jackson Laboratory to develop a novel preclinical mouse model for POLG mitochondrial disorders, Parkinson's disease, and other neurodegenerative mitochondrial diseases in Massachusetts on Sep 15th '26.
- is_developingSep 10, 2026
Mighty continues to develop preclinical asset MYTX-589 for rare mitochondrial disorders.
- is_developingSep 10, 2026
Mighty initiates IND-enabling studies of MYTX-255 for fatty acid oxidation disorders in Massachusetts and plans to submit an IND application by year-end 2027.
For institutional investors. Book with your work email.
Mighty Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Mighty Therapeutics's valuation, stock price, and market status.
Is Mighty Therapeutics a public or private company?
Mighty Therapeutics is a private company.
What is the current stock price of Mighty Therapeutics?
Mighty Therapeutics is a private company, so its shares have no public market price. Caplight tracks Mighty Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Mighty Therapeutics worth (valuation)?
Mighty Therapeutics's valuation is estimated at $27.6M based on funding round data.
Can I buy Mighty Therapeutics stock?
Mighty Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Mighty Therapeutics's last funding round?
Mighty Therapeutics's most recent funding round was Take Private on November 16, 2022.
Who are the main investors in Mighty Therapeutics?
Key investors in Mighty Therapeutics include Jefferies, Morningside Ventures, Evercore, Horizon Technology Finance Corporation, J. Wood Capital Advisors.
Will Mighty Therapeutics IPO soon?
No public IPO plans have been announced for Mighty Therapeutics.
How can I track Mighty Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Mighty Therapeutics's shares on secondary markets.